Adverse events, placebo and nocebo effects in placebo-treated paediatric patients with refractory focal epilepsies. Analysis of double-blind studies

Epilepsy Research

Volumn 108, Issue 10, 2014, Pages 1685-1693

  Zaccara, Gaetano ^a   Giovannelli, Fabio ^a,b   Franco, Valentina ^c,e   Cincotta, Massimo ^a   Tramacere, Luciana ^a   Verrotti, Alberto ^d  

^a Florence Health Authority   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adverse effects; Antiepileptic drugs; Epilepsy; Nocebo effects; Placebo effects; Side effects

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; TOPIRAMATE; ZONISAMIDE;

ABNORMAL THINKING; ANXIETY DISORDER; ATAXIA; DIPLOPIA; DIZZINESS; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HEADACHE; HUMAN; NOCEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CHILD; DOUBLE BLIND PROCEDURE; EPILEPSIES, PARTIAL; PSYCHOLOGY;

ADOLESCENT; ANTICONVULSANTS; CHILD; DOUBLE-BLIND METHOD; EPILEPSIES, PARTIAL; HUMANS; NOCEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84914144492     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2014.09.015     Document Type: Review

References (41)

1. Appleton R., Fichtner K., LaMoreaux L., Alexander J., Halsall G., Murray G., Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Epilepsia 1999, 40:1147-1154.
2. Baker G.A., Camfield C., Camfield P., Cramer J.A., Elger C.E., Johnson A.L., Martins da Silva A., Meinardi H., Munari C., Perucca E., Thorbecke R. Commission on outcome measurement in epilepsy, 1994-1997: final report. Epilepsia 1998, 39:213-231.
3. Carreno M., Gil-Nagel A., Sanchez J.C., Elices E., Serratosa J.M., Salas-Puig J., Villanueva V., Porcel J. Strategies to detect adverse effects of antiepileptic drugs in clinical practice. Epilepsy Behav. 2008, 13:178-183.
4. Colloca L., Miller F.J. Harnessing the placebo effect: the need for translational research. Philos. Trans. R. Soc. London, Ser. B 2011, 366:1922-1930.
5. Duchowny M., Pellock J.M., Graf W.D., Billard C., Gilman J., Casale E., Womble G., Risner M., Manasco P. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999, 53:1724.
6. Elterman R.D., Glauser T.A., Wyllie E., Reife R., Wu S.C., Pledger G. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999, 52:1338-1344.
7. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T., Rintelmann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry 1997, 54:1031-1037.
8. Enck P., Benedetti F., Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008, 59:195-206.
9. Fernandes R., Ferreira J.J., Sampaio C. The placebo response in studies of acute migraine. J. Pediatr. 2008, 152:527-533.
10. Finniss D.G., Kaptchuk T.J., Miller F., Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 20:686-695.
11. Gabapentin Summary of Product Characteristics http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Neurontin/human_referral_000046.jsp(accessed June 16th, 2014) 2014.
12. Gilliam F.G., Fessler A.J., Baker G., Vahle V., Carter J., Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62:23-27.
13. Glauser T.A., Nigro M., Sachdeo R., Pasteris L.A., Weinstein S., Abou-Khalil B., Frank L.M., Grinspan A., Guarino T., Bettis D., Kerrigan J., Geoffroy G., Mandelbaum D., Jacobs T., Mesenbrink P., Kramer L., D'Souza J. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000, 54:2237-2244.
14. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006, 66:1654-1660. N159 Study Group.
15. Guerrini R., Zaccara G., la Marca G., Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf. 2012, 35:519-533.
16. Guerrini R., Rosati A., Segieth J., Pellacani S., Bradshaw K., Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia 2013, 54:1473-1480.
17. Guite J.W., Logan D.E., McCue R., Sherry D.D., Rose J.B. Parental beliefs and worries regarding adolescent chronic pain. Clin. J. Pain. 2009, 25:223-232.
18. Häuser W., Hansen E., Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch. Arztebl. Int. 2012, 109:459-465.
19. Higgins J.P., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A. The cochrane collaboration's tool for assessing risk of bias in randomized trials. BMJ 2011, 343:d5928. Cochrane Bias Methods Group, Cochrane Statistical Methods Group.
20. Johann-Liang R., Wyeth J., Chen M., Cope J.U. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol. Drug Saf. 2009, 18:24-27.
21. Lamotrigine Summary of Product Characteristics http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Lamictal/human_referral_000037.jsp (accessed June 16th, 2014) 2014.
22. Levetiracetam Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000277/WC500041334.pdf(accessed June 16th, 2014) 2014.
23. Levisohn P.M., Mintz M., Hunter S.J., Yang H., Jones J. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009, 50:2377-2389. N01103 Levetiracetam Study Group.
24. Lewis D.W., Winner P., Wasiewski W. The placebo responder rate in children and adolescents. Headache 2005, 45:232-239.
25. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009, 3:e123-e130. PRISMA Group.
26. Mula M., Schmitz B. Depression in epilepsy: mechanisms and therapeutic approach. Ther. Adv. Neurol. Disord. 2009, 2:337-344.
27. Oakley C.B., Kossoff E.H. Migraine and epilepsy in the pediatric population. Curr. Pain Headache Rep. 2014, 18(Mar (402)). 10.1007/s11916-013-0402-3.
28. Oxcarbazepine Summary of Product Characteristics http://mri.medagencies.org/download/DK_H_0171_004_FinalSPC_3of4.pdf[accessed June 16th, 2014] 2014.
29. Perucca E., Beghi E., Dulac O., Shorvon S., Tomson T. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res. 2000, 41:107-139.
30. Perucca E., Kwan P. Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005, 19:897-908.
31. Rheims S., Cucherat M., Arzimanoglou A., Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008, 5(8):e166. (12).
32. Rheims S., Perucca E., Cucherat M., Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011, 52:219-233.
33. Rief W., Nestoriuc Y., Weiss S., Welzel E., Barsky A.J., Hofmann S.G. Metaanalysis of the placebo response in antidepressant trials. J. Affect. Disord. 2009, 118:1-8.
34. Rief W., Bingel U., Schedlowski M., Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin. Pharmacol. Ther. 2011, 90:722-726.
35. Rothner A.D., Wasiewski W., Winner P., Lewis D., Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 2006, 46:101-109.
36. Topiramate Summary of Product Characteristics http://www.hma.eu/fileadmin/dateien/pipar/de1326/spc_de1326topiramat.pdf(accessed June 16th, 2014) 2014.
37. Wallace B.C., Schmid C.H., Lau J., Trikalinos T.A. Meta-analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med. Res. Methodol. 2009, 9:80. 10.1186/1471-2288-9-80.
38. Weimer K., Gulewitsch M.D., Schlarb A.A., Schwille-Kiuntke J., Klosterhalfen S., Enck P. Placebo effects in children: a review. Pediatr. Res. 2013, 74:96-102.
39. Zaccara G., Cincotta M., Borgheresi A., Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord. 2004, 6:153-168.
40. Zaccara G., Giovannelli F., Cincotta M., Loiacono G., Verrotti A. Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials. A systematic review. J. Neurol. 2014, (Jun). (11), [Epub ahead of print].
41. Zonisamide Summary of Product Characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000577/WC500052431.pdf(accessed June 16th, 2014) 2014.